Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, focusing on precision oncology in non-small cell lung cancer (NSCLC), experts Helena Yu, MD; Jacob Sands, MD; and Sarah Goldberg MD, MPH; will discuss the rapidly evolving landscape of Human Epidermal growth factor Receptor 2 (HER2)- and Trophoblast cell-surface antigen 2 (TROP2)-directed therapies in NSCLC. The podcast covers the spectrum of targeted agents from antibody-drug conjugates (ADCs) to novel HER2-selective tyrosine kinase inhibitors (TKIs), along with key clinical trial data and practical strategies for managing the unique adverse event profiles associated with these treatments.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Differentiate the impact of HER2 mutations, amplifications, and HER2 protein overexpression on managing advanced NSCLC
• Construct treatment plans for patients with advanced NSCLC harboring HER2 alterations based on the most up to date clinical trial safety and efficacy data
• Evaluate patient eligibility for TROP2-targeted ADCs in advanced NSCLC with and without targetable genomic alterations
• Formulate plans to mitigate adverse events associated with HER2- and TROP2-directed therapies in NSCLC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

Chair:

Benjamin P. Levy, MD

Associate Professor of Oncology
Johns Hopkins University School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Johnson & Johnson (Janssen), Merck, Pfizer

Sarah Goldberg, MD, MPH

Professor of Internal Medicine
Co-Director, Center for Thoracic Cancers
Chief, Thoracic Oncology
Yale School of Medicine
New Haven, CT

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Johnson & Johnson, Merck, Regeneron, Summit Therapeutics, Synthekine, Tubulis; Grant/Research Funding: Adela, AstraZeneca, Boehringer Ingelheim, Mirati

Jacob Sands, MD

Associate Chief, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Fosun, Genentech, Gilead, Jazz Pharmaceuticals, Medtronic, Merck, Novartis, Pfizer, Sanofi; Grant/Research Funding: Amgen, Harpoon, Novartis

Helena Yu, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Amgen, AstraZeneca, Black Diamond, Bristol Myers Squibb, Daiichi, Janssen, Pfizer, Taiho; Grant/Research Funding (to institution): AstraZeneca, Cullinan, Daiichi, Janssen, Kumquat, Pfizer, SystImmune, Taiho

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including case-based panel discussions and expert debate on treatment sequencing across HER2- and TROP2-directed therapies, go to https://www.gotoper.com/courses/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care-mr5q.

Release Date

July 7, 2026

Expiration Date

July 7, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.